Prove ADCC Activity
in real human skin
For therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.
Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear.
HypoSkin® offers a solution
Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm the effects of engineered antibodies.
A recent study showed how HypoSkin helped validate Fc-enhanced anti-KIT antibodies for mastocytosis—revealing functional immune engagement at the tissue level.
Don’t just bind—deplete.
Download the study poster to see how HypoSkin can help you:
- Demonstrate tissue-level ADCC
- De-risk early immunotherapy development
Translate in vitro findings into clinical relevance
Please fill in the form below to access our poster.
Author
Comments are closed.